UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MEDTRONIC, INC. and MEDTRONIC VASCULAR, INC.,
`Petitioners,
`
`v.
`
`TELEFLEX LIFE SCIENCES LIMITED,
`Patent Owner
`
`IPR2020-01343
`Patent RE46,116 E
`
`PETITIONERS MEDTRONIC, INC. AND MEDTRONIC VASCULAR,
`INC.’S NOTICE OF APPEAL UNDER 37 C.F.R. § 90.2(a)
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MEDTRONIC, INC. and MEDTRONIC VASCULAR, INC.,
`Petitioners,
`
`v.
`
`TELEFLEX LIFE SCIENCES LIMITED,
`Patent Owner
`
`IPR2020-01343
`Patent RE46,116 E
`
`PETITIONERS MEDTRONIC, INC. AND MEDTRONIC VASCULAR,
`INC.’S NOTICE OF APPEAL UNDER 37 C.F.R. § 90.2(a)
`
`
`
`
`
`
`
`
`
`
`Pursuant to 35 U.S.C. §§ 141-144, 319, and 37 C.F.R.§ 90.2(a), notice is
`
`hereby given that Petitioners Medtronic, Inc. and Medtronic Vascular, Inc.
`
`(“Medtronic”) appeal to the United States Court of Appeals for the Federal Circuit
`
`from the Final Written Decision (“Final Written Decision”) (Paper No. 85, dated
`
`February 23, 2022) entered by the United States Patent and Trademark Office,
`
`Patent Trial and Appeal Board (“Board”) in IPR2020-01343, and from all
`
`underlying orders, decisions, rulings, and opinions. A copy of the Final Written
`
`Decision is attached hereto as Exhibit A.
`
`In accordance with 37 C.F.R. § 90.2(a)(3)(ii), Medtronic further indicates
`
`that the issues on appeal may include, but are not limited to, whether the Board
`
`erred in determining that claims 25-40, 42, and 44-48 of U.S. Patent Number
`
`RE46,116 were not shown to be unpatentable under 35 U.S.C. § 103, any findings
`
`supporting or related to the Board’s determination, and all other issues decided
`
`adversely to Medtronic in any order, decision, ruling, and/or opinion, including but
`
`not limited to the Board’s failure to properly consider evidence of record, the
`
`Board’s legal errors in undertaking the obviousness analysis, and the Board’s
`
`findings that conflict with the evidence of record and are not supported by
`
`substantial evidence.
`
`Simultaneous with this submission, a copy of this Notice of Appeal is being
`
`filed through the Patent Trial and Appeal Board End to End (“PTAB E2E”)
`
`1
`
`
`
`System. In addition, a copy of the Notice of Appeal, along with the required
`
`docketing fee, is being filed with the Clerk of Court for the United States Court of
`
`Appeals for the Federal Circuit.
`
`
`
`Dated: April 22, 2022
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Cyrus A. Morton
`Cyrus A. Morton
`ROBINS KAPLAN LLP
`800 LaSalle Avenue, Suite 2800
`Minneapolis, MN 55402
`(612) 349-8500
`Attorney for Petitioners
`
`
`
`2
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on this April 22, 2022, a copy of Petitioners Medtronic,
`
`Inc. and Medtronic Vascular, Inc.’s Notice of Appeal Under 37 C.F.R. § 90.2(a)
`
`was served in its entirety by electronic mail on Patent Owner’s counsel at the
`
`following addresses included in Patent Owner’s Mandatory Notices:
`
`J. Derek Vandenburgh, Reg. No. 32,179
`dvandenburgh@carlsoncaspers.com
`
`Dennis C. Bremer, Reg. No. 40,528
`dbremer@carlsoncaspers.com
`
`Joseph W. Winkels
`jwinkels@carlsoncaspers.com
`
`Peter M. Kohlhepp
`pkohlhepp@carlsoncaspers.com
`
`Tara C. Norgard
`tnorgard@carlsoncaspers.com
`
`Megan E. Christner, Reg. No. 78,979
`mchristner@carlsoncaspers.com
`
`Shelleaha L. Jonas
`sjonas@carlsoncaspers.com
`
`
`Dated: April 22, 2022
`
`
`
`
`
`Respectfully submitted,
`/s/ Cyrus A. Morton
`Cyrus A. Morton
`Reg. No. 44,954
`Attorney for Petitioners
`
`
`
`3
`
`
`
`
`
`
`Exhibit A
`Exhibit A
`
`
`
`Trials@uspto.gov
`571-272-7822
`
`Paper 85
`Entered: February 23, 2022
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MEDTRONIC, INC. AND MEDTRONIC VASCULAR,INC.,
`Petitioner,
`
`V.
`
`TELEFLEX LIFE SCIENCES LIMITED,
`Patent Owner.
`
`IPR2020-01343
`Patent RE46,116 E
`
` ÿÿ
`
`
` ÿ
` ÿ ÿÿ ÿ
`ÿ
`!"# $ÿ% &